In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


William Looney

Executive Editor

New York, NY
Set Alert for Articles By William Looney

Latest From William Looney

Will Advanced Technology Simulations Lead To More And Better Drugs? Start-Up Schrodinger Says It Can

Schrodinger LLC is a leading player in the emerging high-stakes field of computational chemical simulation software to boost the quality and productivity of drug discovery and lead generation. Its business model relies heavily on validating theoretical concepts of science and engineering in real-world settings through partnerships with a blue-chip list of pharma and biotech companies.

Digital Health Innovation

Cross-Country Collaboration: With Schrodinger Technology at the Core

Schrodinger pact with MaRS Innovation aims to tackle anti-fungal resistance.
Digital Health Innovation

Data And The Digital Horizon: Perspective From The Agency C-suite

While digital health applications represent a major opportunity for biopharma, acting on the premise – and realizing its promise – depends on quantum-level shifts in organizational design and cultural resilience to disruptive change.  In an In Vivo interview, Omnicom Health Group’s SVP for Data Solutions Christina Kim says industry progress toward a digitized future varies, but the necessity to act is clear. 

Digital Health Business Strategies

GE Healthcare’s New Value Proposition: The Strategic Language Of Software

For an industry whose central structural dilemma is the slow pace of progress from bench to bedside, GE stands out as an exemplar of success – its performance on speed-to-market product launch has been studied extensively by big pharma strategists. GE Healthcare’s Tom McGuinness tells In Vivo how his division is doubling down on this record, using software and data analytics to help biopharma become more efficient in moving products to patients.

BioPharmaceutical Business Strategies

Biopharma 2018: Is There Still A Place For Pharma In The New Health Care Economy?

2018 will be a time of transition in health care, when biopharma’s counterparts in adjacent industry segments scale up in a radical redesign of their traditional business models. Biopharma is not moving as quickly, and it confronts a strategic dilemma on how to address the prospect of a much more powerful set of rivals in the ongoing battle to own the patient experience in medicine.

BioPharmaceutical Business Strategies

Deals Driving Oncology: ImmunoGen CEO Mark Enyedy on Biopharma’s Year Ahead

Cancer continues to reign in 2018 as the emperor of all maladies, with almost boundless opportunities for companies with a solid base in new science and a differentiated therapy set that can be tailored to the needs of individual patients not served by the current standard of care. ImmunoGen CEO Mark Enyedy tells In Vivo that there’s never been a better time for drugmakers in the oncology marketplace.

Deals Leadership
See All